| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.005 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.007 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.095 | 0.008 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.1 | 0.008 |